Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
about
Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cellsPathways to tamoxifen resistance.Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cellsFulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 AbundanceComplex prolactin crosstalk in breast cancer: new therapeutic implicationsHOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.Anastrozole for breast cancer: recent advances and ongoing challenges.Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?Mechanisms of endocrine resistance in breast cancer.A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expressionMultifactorial ERβ and NOTCH1 control of squamous differentiation and cancer.Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
P2860
Q24594804-0A463AE8-56ED-4B00-9AD1-CF9AB742E848Q30441001-0E6A1298-9FD1-481B-B482-203BB7B811FCQ33817324-7091A704-7A3A-46C9-B859-BC974B969305Q34626963-CADEDB95-C1B3-4F3F-8FDF-DF8A556AC0B0Q35182591-31214EE9-CD9C-4F99-A90C-5234E4A38523Q35303180-9CA2303C-D5E0-49D1-88A2-6CDFE138FD17Q36029524-A390E642-93C8-4703-A264-042A80F0D856Q36415623-A09035F0-29C0-46F3-91A4-AE5EE37BD3ABQ36458731-CBEB98F4-EDB8-47B5-B718-E2EA7935FBA9Q36500527-4F946435-F7ED-48BD-A16B-A7F8A1EA939AQ36574547-91725486-3614-4F4C-AFAD-4C1FEE5DD58BQ36851417-3AC60D2E-B11A-4ACC-901C-3C79624145D5Q36903310-040367F9-E511-4D57-8302-E7C99F32DA7BQ37360151-F06F583A-87D0-4A51-8C55-8BF90288FBF8Q37707677-72FF121D-F9AB-4C23-8AAB-BAC93C56927FQ37728495-D0806392-7CF6-4C05-8A34-FC3144AFB9E8Q39667297-99BCB325-FE2D-4A4C-9EA5-E1D18FA7F031Q39779772-5FBD5BA1-63D3-4555-AEE8-9CDB22CB9664Q47394260-EEE77A43-343F-4FA6-BBAE-01DA88327E21Q57107345-774FF6AD-44BD-4B38-B511-ED0AA583C8E2
P2860
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Biological characteristics of ...... ercoming endocrine resistance.
@ast
Biological characteristics of ...... ercoming endocrine resistance.
@en
type
label
Biological characteristics of ...... ercoming endocrine resistance.
@ast
Biological characteristics of ...... ercoming endocrine resistance.
@en
prefLabel
Biological characteristics of ...... ercoming endocrine resistance.
@ast
Biological characteristics of ...... ercoming endocrine resistance.
@en
P1476
Biological characteristics of ...... ercoming endocrine resistance.
@en
P2093
Richard J Pietras
Robert I Nicholson
P2888
P356
10.1007/S10549-005-9037-3
P407
P478
93 Suppl 1
P577
2005-01-01T00:00:00Z